MLN1117

DRUG3 trials

Sponsors

Millennium Pharmaceuticals, Inc.

Conditions

Advanced and Metastatic Gastric or Gastroesophageal AdenocarcinomaClear-cell Metastatic Renal Cell CarcinomaEndometrial Neoplasms

Phase 1

MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma

TerminatedNCT02551055

Millennium Pharmaceuticals, Inc.Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

Start: 2015-10-15End: 2017-02-17Updated: 2019-09-20

Phase 2

A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer

CompletedNCT02725268

Millennium Pharmaceuticals, Inc.Endometrial Neoplasms

Start: 2016-04-01End: 2020-10-30Updated: 2021-11-24

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

CompletedNCT02724020

Millennium Pharmaceuticals, Inc.Clear-cell Metastatic Renal Cell Carcinoma

Start: 2016-06-30End: 2020-10-13Updated: 2021-11-19

Related Papers

A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer

Gynecologic Oncology2023-10-149 citations

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.

2021-11-297 citations

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.

2020-09-1170 citations

Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors

Clinical Pharmacology in Drug Development2020-06-0212 citations

Randomized phase II study of sapanisertib (SAP) + paclitaxel (PAC) versus PAC alone in patients (pts) with advanced, recurrent, or persistent endometrial cancer.

Journal of Clinical Oncology2020-05-207 citations